ActHIB and OmniHIB market outlook points to steady growth through 2030

The global market for ActHIB and OmniHIB vaccines is expected to expand through 2030 as Hib infection prevention remains a priority for infants and young children. The outlook is being driven by vaccination campaigns, higher healthcare spending, and broader immunization programs, with Asia-Pacific expected to grow fastest.

Why it matters: - ActHIB and OmniHIB vaccines help prevent invasive Haemophilus influenzae type b infections, including meningitis and pneumonia, in infants and young children. - Market growth matters because wider vaccine access can reduce serious bacterial disease in unvaccinated populations. - The forecast highlights where immunization coverage, public funding, and vaccine logistics may shape demand through 2030.

What happened: - The Business Research Company published its ActHIB and OmniHIB Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Oct. 29, 2026. - The report projects continued expansion in the ActHIB and OmniHIB market through the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is projected to post the fastest growth during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa.

The details: - ActHIB is a conjugate vaccine that links the Hib capsular polysaccharide to a protein to stimulate immunity. - OmniHIB is a similar conjugate vaccine. - Both vaccines are primarily given to infants and young children. - The report links past market growth to high Hib infection rates, vaccine effectiveness, global child immunization efforts, public health funding, and early inclusion in vaccination schedules. - Expected demand growth is tied to efforts to improve infant immunization coverage, especially in emerging economies. - Government-backed vaccination campaigns, better vaccine access and logistics, and rising awareness of preventable bacterial meningitis are supporting the outlook. - Routine pediatric vaccine demand remains steady. - Combination vaccines for children are being used more widely. - National immunization programs are expanding. - Cold chain infrastructure is improving. - The report identifies rising Hib infection prevalence as a demand driver for ActHIB and OmniHIB. - Hib infections can cause meningitis, pneumonia, and epiglottitis. - Lower vaccination rates can weaken herd immunity and increase vulnerability to infection. - Australian Institute of Health and Welfare data from October 2025 showed that 94% of Australian 1-year-olds and 93% of 2-year-olds had completed Hib vaccination in 2023. - The report also cites rising healthcare spending as a market driver. - The UK's Office for National Statistics reported total healthcare spending rose 5.6% in 2023 from the prior year, following 0.9% growth over 2022. - Increased healthcare budgets can support broader routine immunization access and stronger national vaccination programs. - Research and development spending is another growth factor. - Eurostat reported in July 2025 that government funding for R&D in the European Union rose 3.4% in 2024 to about €127,916 million from €123,675 million in 2023. - The report points to vaccine formulation improvements, higher immunogenicity, and more efficient production as R&D outcomes. - Innovations in conjugation technology, vaccine stability, and combination vaccine options are expected to improve access and protection. - The report also highlights updated analytics features, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables. - The report offers a free sample and full report through The Business Research Company’s website, including the free sample and the full market report.

Between the lines: - The outlook suggests vaccine demand is being shaped by both disease burden and health-system capacity. - Markets with stronger immunization coverage may see steadier routine demand, while regions with lower coverage could face greater pressure to expand vaccination programs. - The report’s emphasis on combination vaccines and cold chain infrastructure points to distribution and administration efficiency as commercial advantages.

What's next: - The market is expected to keep growing as governments expand child immunization programs and improve vaccine access. - Asia-Pacific appears positioned for the fastest growth as emerging economies increase coverage and public health investment. - Ongoing R&D and infrastructure upgrades are likely to influence product uptake and regional market share over the forecast period.